Mindstate Design Labs, backed by prominent Silicon Valley investors, has leveraged artificial intelligence to design a novel psychoactive compound that avoids classic psychedelic hallucinations. The AI platform linked biochemical data with thousands of trip reports to identify a formulation of 5-MeO-MiPT, called MSD-001, that activates serotonin‑2A receptors without producing a full "trip." In a Phase I trial with healthy volunteers, MSD‑001 was safe, well tolerated, and produced heightened emotions and perceptual changes without hallucinations. The company aims to use this "psychedelic tofu" as a base for future therapeutics targeting mood and anxiety disorders. Leer más →